Look! Cannabis Company To Reproduce Rare Cannabinoids

As the stigma around marijuana changes, so do the studies and experiments. Today the word comes down that the Boston-based biotech firm Gingko Bioworks Inc. has announced a partnership with Canadian cannabis company Cronos Group Inc. The two companies will come together to work on a groundbreaking innovation in cannabis production. They are looking to use plant DNA to genetically (re)produce cannabinoids directly. Gingko is working for Cronos to develop methods for engineering cannabis’ active compounds genetically.

They are looking to isolate the rare, trace cannabinoids in the cannabis plant and sequence the parts of the genome responsible for producing them. It will then use the DNA to artificially produce the rare cannabinoids in large quantities. Reproducing cannabinoids directly from DNA without growing plants has some major advantages. IT’s not subject to climate or growing conditions or regional variables, while also being more consistent, predictable and more cost-effective.

Gingko CEO Jason Kelley stated: “The reality is that brewery economics is going to wipe the floor with farming economics.” Speak your thoughts on the news below and stay tuned for much more on this coming very soon.